Menu Search
Equities

Medicenna Therapeutics Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MDNAF:QXE

Medicenna Therapeutics Corp

Actions
  • Price (USD)0.6238
  • Today's Change0.014 / 2.26%
  • Shares traded33.93k
  • 1 Year change-29.93%
  • Beta1.8218
Data delayed at least 15 minutes, as of Feb 18 2026 15:16 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-13.82m
  • Incorporated2015
  • Employees18.00
  • Location
    Medicenna Therapeutics Corp2 Bloor St W., 7Th FloorTORONTO M4W 3E2CanadaCAN
  • Phone+1 (416) 648-5555
  • Fax+1 (416) 648-5555
  • Websitehttps://www.medicenna.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.